共同药业(300966.SZ)发布前三季度业绩，归母净亏损3243.49万元

Core Viewpoint - The company reported a revenue increase of 24.54% year-on-year for the first three quarters of 2025, but also recorded a net loss attributable to shareholders of 32.43 million yuan [1] Financial Performance - The company's operating revenue for the first three quarters reached 455 million yuan [1] - The net loss attributable to shareholders was 32.43 million yuan [1] - The net loss after deducting non-recurring gains and losses was 32.21 million yuan [1] - The basic loss per share was 0.28 yuan [1]